FilingPulse

ALGS insider filings

Aligos Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-06-29. Screen ALGS transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for ALGS between 2026-07-10 and 2026-10-08. The table below lists the most recent filings on record.

Recent insider filings — Aligos Therapeutics, Inc.

FiledFormInsiderReported transactionsSource
2026-06-294Chavez Margarita — DirectorGrant/award (A): 5,860 (derivative) @ $0EDGAR
2026-06-294Hirth Peter — DirectorGrant/award (A): 5,860 (derivative) @ $0EDGAR
2026-06-294Nuechterlein Carole — DirectorGrant/award (A): 5,860 (derivative) @ $0EDGAR
2026-06-294Martell Bridget A — DirectorGrant/award (A): 5,860 (derivative) @ $0EDGAR
2026-06-294Preston Heather — DirectorGrant/award (A): 5,860 (derivative) @ $0EDGAR
2026-06-294Scopa James Paul — DirectorGrant/award (A): 5,860 (derivative) @ $0EDGAR
2026-03-114Symons Julian A. — See RemarksGrant/award (A): 23,310 (derivative) @ $0EDGAR
2026-03-114Aneja Nikhil — Principal Accounting OfficerGrant/award (A): 9,450 (derivative) @ $0EDGAR
2026-03-114Calhoun Lesley Ann — See RemarksGrant/award (A): 37,485 (derivative) @ $0EDGAR
2026-03-114BLATT LAWRENCE — President and CEO, DirectorGrant/award (A): 105,840 (derivative) @ $0EDGAR
2025-07-184Symons Julian A. — See RemarksGrant/award (A): 16,000 (derivative) @ $0EDGAR
2025-07-184Calhoun Lesley Ann — See RemarksGrant/award (A): 40,185 (derivative) @ $0EDGAR
2025-07-184BLATT LAWRENCE — President and CEO, DirectorGrant/award (A): 179,800 (derivative) @ $0EDGAR
2025-06-264Hirth Peter — DirectorGrant/award (A): 5,860 (derivative) @ $0EDGAR
2025-06-264Chavez Margarita — DirectorGrant/award (A): 5,860 (derivative) @ $0EDGAR
2025-06-264Nuechterlein Carole — DirectorGrant/award (A): 5,860 (derivative) @ $0EDGAR
2025-06-264Martell Bridget A — DirectorGrant/award (A): 5,860 (derivative) @ $0EDGAR
2025-06-264Preston Heather — DirectorGrant/award (A): 5,860 (derivative) @ $0EDGAR
2025-06-264Scopa James Paul — DirectorGrant/award (A): 5,860 (derivative) @ $0EDGAR
2025-03-044Symons Julian A. — See RemarksGrant/award (A): 21,693 (derivative) @ $0EDGAR
2025-03-044Calhoun Lesley Ann — See RemarksGrant/award (A): 47,271 (derivative) @ $0EDGAR
2025-03-044BLATT LAWRENCE — President and CEO, DirectorGrant/award (A): 140,103 (derivative) @ $0EDGAR
2024-10-104Achneck Hardean — Chief Medical OfficerGrant/award (A): 75,000 (derivative) @ $0EDGAR
2024-09-064Symons Julian A. — See RemarksGrant/award (A): 10,880 (derivative) @ $0EDGAR
2024-09-064Calhoun Lesley AnnGrant/award (A): 10,880 (derivative) @ $0EDGAR
2024-09-064BLATT LAWRENCE — Chief Executive Officer, DirectorGrant/award (A): 33,920 (derivative) @ $0EDGAR
2024-08-094Chavez Margarita — DirectorGrant/award (A): 120,000 (derivative) @ $0EDGAR
2024-08-094Preston Heather — DirectorGrant/award (A): 120,000 (derivative) @ $0EDGAR
2024-06-284Hirth Peter — DirectorGrant/award (A): 60,000 (derivative) @ $0EDGAR
2024-06-284Nuechterlein Carole — DirectorGrant/award (A): 60,000 (derivative) @ $0EDGAR
2024-06-284Martell Bridget A — DirectorGrant/award (A): 60,000 (derivative) @ $0EDGAR
2024-06-284Scopa James Paul — DirectorGrant/award (A): 60,000 (derivative) @ $0EDGAR
2024-03-044McClure Matthew W. — Chief Medical OfficerGrant/award (A): 72,000 (derivative) @ $0EDGAR
2024-03-044Symons Julian A. — See RemarksGrant/award (A): 72,000 (derivative) @ $0EDGAR
2024-03-044Calhoun Lesley AnnGrant/award (A): 308,940 (derivative) @ $0EDGAR
2024-03-044BLATT LAWRENCE — Chief Executive Officer, DirectorGrant/award (A): 965,435 (derivative) @ $0EDGAR
2024-02-284Hirth Peter — DirectorDisposition to issuer (D): 15,000 (derivative) @ $0 · Grant/award (A): 4,411 (derivative) @ $0EDGAR
2024-02-284McClure Matthew W. — Chief Medical OfficerDisposition to issuer (D): 255,626 (derivative) @ $0 · Disposition to issuer (D): 92,000 (derivative) @ $0 · Disposition to issuer (D): 23,000 (derivative) @ $0 · Grant/award (A): 75,183 (derivative) @ $0 · Grant/award (A): 65,713 (derivative) @ $0 · Grant/award (A): 16,428 (derivative) @ $0EDGAR
2024-02-284Symons Julian A. — See RemarksDisposition to issuer (D): 200,000 (derivative) @ $0 · Disposition to issuer (D): 105,000 (derivative) @ $0 · Disposition to issuer (D): 26,250 (derivative) @ $0 · Grant/award (A): 58,822 (derivative) @ $0 · Grant/award (A): 74,998 (derivative) @ $0 · Grant/award (A): 18,750 (derivative) @ $0EDGAR
2024-02-284Calhoun Lesley AnnDisposition to issuer (D): 176,237 (derivative) @ $0 · Disposition to issuer (D): 105,000 (derivative) @ $0 · Disposition to issuer (D): 26,250 (derivative) @ $0 · Grant/award (A): 51,833 (derivative) @ $0 · Grant/award (A): 74,998 (derivative) @ $0 · Grant/award (A): 18,750 (derivative) @ $0EDGAR
2024-02-284Nuechterlein Carole — DirectorDisposition to issuer (D): 15,000 (derivative) @ $0 · Grant/award (A): 4,411 (derivative) @ $0EDGAR
2024-02-284Martell Bridget A — DirectorDisposition to issuer (D): 30,000 (derivative) @ $0 · Grant/award (A): 8,823 (derivative) @ $0EDGAR
2024-02-284Nielsen Jack — DirectorDisposition to issuer (D): 15,000 (derivative) @ $0 · Grant/award (A): 4,411 (derivative) @ $0EDGAR
2024-02-284Scopa James Paul — DirectorDisposition to issuer (D): 30,000 (derivative) @ $0 · Grant/award (A): 8,823 (derivative) @ $0EDGAR
2024-02-284BLATT LAWRENCE — Chief Executive Officer, DirectorDisposition to issuer (D): 450,000 (derivative) @ $0 · Disposition to issuer (D): 323,400 (derivative) @ $0 · Disposition to issuer (D): 80,850 (derivative) @ $0 · Grant/award (A): 132,352 (derivative) @ $0 · Grant/award (A): 230,999 (derivative) @ $0 · Grant/award (A): 57,749 (derivative) @ $0EDGAR
2023-10-274Nuechterlein Carole — Director, 10% ownerPurchase (P): 7,933,601 @ $0.76 · Purchase (P): 3,966,800 (derivative) @ $0.12EDGAR
2023-10-274Scopa James Paul — DirectorGrant/award (A): 183,083 @ $0.76 · Grant/award (A): 91,541 (derivative) @ $0.12EDGAR
2023-10-274BLATT LAWRENCE — Chief Executive Officer, DirectorGrant/award (A): 610,277 @ $0.76 · Grant/award (A): 305,138 (derivative) @ $0.12EDGAR
2023-09-124Calhoun Lesley AnnGrant/award (A): 48,000 (derivative) @ $0EDGAR
2023-09-124BLATT LAWRENCE — Chief Executive OfficerGrant/award (A): 150,000 (derivative) @ $0EDGAR

Recent 8-K events — Aligos Therapeutics, Inc.

FiledFormItems reportedSource
2026-09-158-K1.01 — Entry into a Material Definitive AgreementEDGAR
2026-08-068-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2026-06-268-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits		EDGAR
2026-05-078-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2026-04-218-K1.01 — Entry into a Material Definitive AgreementEDGAR
2026-04-148-K8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
2026-03-058-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2026-02-048-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2025-11-068-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2025-08-068-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=ALGS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →